Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
10-Q
2024 Q1
Quarterly report
24 Apr 24
8-K
First quarter revenue $2.3 billion; GAAP diluted EPS $2.70; Non-GAAP diluted EPS $3.67
24 Apr 24
PRE 14A
Preliminary proxy
12 Apr 24
10-K
2023 FY
Annual report
13 Feb 24
8-K
Biogen reports fourth quarter and full year 2023 results and expects return to Non-GAAP EPS growth in 2024
13 Feb 24
8-K
Amendments to Articles of Incorporation or Bylaws
12 Dec 23
8-K
Departure of Directors or Certain Officers
8 Nov 23
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Biogen reports third quarter 2023 results and updates full year 2023 guidance
8 Nov 23
8-K/A
Submission of Matters to a Vote of Security Holders
28 Sep 23
8-K
Biogen Completes Acquisition of Reata Pharmaceuticals
26 Sep 23
8-K
Entry into a Material Definitive Agreement
1 Sep 23
DEFA14A
Additional proxy soliciting materials
31 Jul 23
8-K
Entry into a Material Definitive Agreement
31 Jul 23
DEFA14A
Additional proxy soliciting materials
28 Jul 23
8-K
Other Events
28 Jul 23
10-Q
2023 Q2
Quarterly report
25 Jul 23
8-K
Second quarter revenue $2,456 million; GAAP diluted EPS $4.07; Non-GAAP diluted EPS $4.02
25 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
29 Jun 23
DEFA14A
Additional proxy soliciting materials
13 Jun 23
DEFR14A
Revised proxy
13 Jun 23
DEFA14A
Additional proxy soliciting materials
12 Jun 23
8-K
Other Events
3 May 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
ARS
2023 FY
Annual report to shareholders
28 Apr 23
10-Q
2023 Q1
Quarterly report
25 Apr 23
8-K
Company reports first quarter 2023 results and reaffirms full year 2023 guidance
25 Apr 23
8-K
Amendments to Articles of Incorporation or Bylaws
18 Apr 23
8-K
Departure of Directors or Certain Officers
8 Mar 23
10-K
2022 FY
Annual report
15 Feb 23
8-K
Biogen advances significant potential growth drivers; Company reports full year 2022 results and provides full year 2023 guidance
15 Feb 23
8-K
Biogen Names Christopher Viehbacher President and Chief Executive Officer
10 Nov 22
10-Q
2022 Q3
Quarterly report
25 Oct 22
8-K
Biogen Reports Third Quarter 2022 Results
25 Oct 22
10-Q
2022 Q1
Quarterly report
20 Jul 22
8-K/A
Biogen Reports Second Quarter 2022 Results
20 Jul 22
Latest ownership filings
4
Adam Keeney
3 May 24
4
Priya Singhal
3 Apr 24
4
Nicole Murphy
3 Apr 24
144
Notice of proposed sale of securities
2 Apr 24
4
Priya Singhal
26 Feb 24
144
Notice of proposed sale of securities
22 Feb 24
4
SUSAN H ALEXANDER
21 Feb 24
4
Ginger Gregory
21 Feb 24
4
Rachid Izzar
21 Feb 24
4
Robin Kramer
21 Feb 24
4
MICHAEL R MCDONNELL
21 Feb 24
4
Nicole Murphy
21 Feb 24
4
Priya Singhal
21 Feb 24
144
Notice of proposed sale of securities
21 Feb 24
4
Eric K Rowinsky
20 Feb 24
4
Ginger Gregory
13 Feb 24
4
Priya Singhal
13 Feb 24
4
Nicole Murphy
13 Feb 24
4
MICHAEL R MCDONNELL
13 Feb 24
4
Robin Kramer
13 Feb 24
4
Rachid Izzar
13 Feb 24
4
SUSAN H ALEXANDER
13 Feb 24
SC 13G/A
SANGAMO THERAPEUTICS, INC
12 Feb 24
SC 13G/A
Denali Therapeutics Inc.
12 Feb 24
SC 13G/A
PRIMECAP MANAGEMENT CO/CA/
12 Feb 24
SC 13G/A
VANGUARD GROUP INC
12 Feb 24
144
Notice of proposed sale of securities
12 Feb 24
SC 13G/A
VANGUARD GROUP INC
12 Feb 24
4
SUSAN H ALEXANDER
9 Feb 24
4
Ginger Gregory
9 Feb 24
4
Jane Grogan
9 Feb 24
4
Rachid Izzar
9 Feb 24
4
Adam Keeney
9 Feb 24
4
Robin Kramer
9 Feb 24
4
MICHAEL R MCDONNELL
9 Feb 24
4
Nicole Murphy
9 Feb 24
4
Priya Singhal
9 Feb 24
4
Christopher Viehbacher
9 Feb 24
4
Priya Singhal
5 Feb 24
144
Notice of proposed sale of securities
2 Feb 24